DEVELOPMENT OF A NOVEL IN SITU GELLING INTRANASAL SYSTEM CONTAINING RESVERATROL LOADED PLGA NANOPARTICLES FOR MANAGEMENT OF EPILEPSY

Drug delivery to the brain is highly challenging due to the blood-brain barrier (BBB). Resveratrol (RESV) has antioxidant and neuroprotective effects but limited bioavailability caused by low solubility, photosensitivity and rapid metabolism. This study develops an intranasal in situ gel containing RESVloaded PLGA nanoparticles for targeted nose-to-brain delivery in epilepsy management. The gel uses thermosensitive Kolliphor® P 407, mucoadhesive HPMC K-100, and mannitol for tonicity. It was characterized for particle size, gelation, entrapment efficiency, drug content, and stability and evaluated through in vitro and in vivo studies, offering a promising alternative treatment for epilepsy.